Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic Therapy For Onychomycosis
NCT07756671Phase 1Active, not recruiting
- Sponsor
- UTHealth Houston
- Start
- Aug 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aminolevulinic acid 10% gel in onychomycosis, sponsored by UTHealth Houston. Primary endpoints: Clinical clearance of onychomycosis at 6 months and Mycological clearance of onychomycosis at 6 months. Started Aug 2026; status: active, not recruiting.
02
Drugs
aminolevulinic acid 10% gel
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT07756671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756671.